BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20739041)

  • 1. [Behavioral disorders in Parkinson's disease: from pathophysiology to the mastery of dopaminergic treatment].
    Thobois S; Ardouin C; Schmitt E; Lhommée E; Klinger H; Xie J; Lagrange C; Kistner A; Aya Kombo M; Fleury V; Poisson A; Fraix V; Broussolle E; Pollak P; Krack P
    Rev Neurol (Paris); 2010 Oct; 166(10):816-21. PubMed ID: 20739041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease].
    Ardouin C; Chéreau I; Llorca PM; Lhommée E; Durif F; Pollak P; Krack P;
    Rev Neurol (Paris); 2009 Nov; 165(11):845-56. PubMed ID: 19683776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review.
    Béreau M; Fleury V; Bouthour W; Castrioto A; Lhommée E; Krack P
    Rev Neurol (Paris); 2018 Nov; 174(9):653-663. PubMed ID: 30224159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Behavioral disorders in Parkinson's disease. Genetic, pharmacological and medico-legal aspects].
    Sobrido MJ; Dias-Silva JJ; Quintáns B
    Rev Neurol; 2009 Jan; 48 Suppl 1():S43-8. PubMed ID: 19222015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and therapy of Parkinson's disease].
    Wittstock M; Benecke R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral, neuropsychiatric and cognitive disorders in Parkinson's disease patients with and without motor complications.
    Solla P; Cannas A; Floris GL; Orofino G; Costantino E; Boi A; Serra C; Marrosu MG; Marrosu F
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1009-13. PubMed ID: 21324349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuropsychiatric disorders in Parkinson's disease].
    Noé-Sebastián E; Irimia-Sieira P; Pomares-Arias E; Martínez-Vila E; Luquin-Piudo MR
    Rev Neurol; 2001 Apr 1-15; 32(7):676-81. PubMed ID: 11391498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of parkinsonism and legal capacity].
    Wallesch CW
    Fortschr Neurol Psychiatr; 2011 Aug; 79(8):441. PubMed ID: 21809256
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of the behavioral aspects of Parkinson's disease.
    Borek LL; Chou KL; Friedman JH
    Expert Rev Neurother; 2007 Jun; 7(6):711-25. PubMed ID: 17563253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
    Destée A; Bordet R
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S69-82. PubMed ID: 12690666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease.
    Merims D; Giladi N
    Parkinsonism Relat Disord; 2008; 14(4):273-80. PubMed ID: 17988927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapy for Parkinson's disease.
    Hermanowicz N
    Semin Neurol; 2007 Apr; 27(2):97-105. PubMed ID: 17390254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Startling facts about emotion in Parkinson's disease: blunted reactivity to aversive stimuli.
    Bowers D; Miller K; Mikos A; Kirsch-Darrow L; Springer U; Fernandez H; Foote K; Okun M
    Brain; 2006 Dec; 129(Pt 12):3356-65. PubMed ID: 17095520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
    Wenzelburger R
    Clin Neurophysiol; 2005 Sep; 116(9):1997-8. PubMed ID: 16055380
    [No Abstract]   [Full Text] [Related]  

  • 15. [Non-dopaminergic treatments for Parkinson's disease].
    Derkinderen P
    Rev Neurol (Paris); 2010 Oct; 166(10):811-5. PubMed ID: 20832090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic dysregulation syndrome in Parkinson's disease.
    Katzenschlager R
    J Neurol Sci; 2011 Nov; 310(1-2):271-5. PubMed ID: 21868039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Punding in Parkinson's disease.
    O'Sullivan SS; Evans AH; Lees AJ
    Pract Neurol; 2007 Nov; 7(6):397-9. PubMed ID: 18024780
    [No Abstract]   [Full Text] [Related]  

  • 19. [Psychiatric complications of Parkinson's disease: their symptoms and treatment].
    Castro-García A; Sesar-Ignacio A; Ares-Pensado B
    Rev Neurol; 2004 Oct 1-15; 39(7):646-50. PubMed ID: 15490352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of hedonistic homeostatic dysregulation.
    Kessel BL
    Age Ageing; 2006 Sep; 35(5):540-1. PubMed ID: 16799178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.